Filtered By:
Condition: Pain
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 126 results found since Jan 2013.

ESO Launches 2018 ESO EMS Index to Track Nationwide EMS Performance Across Five Metrics
AUSTIN, Texas – ESO Solutions, Inc., the leading data and software company serving emergency medical services (EMS), hospitals and fire departments, today announced the findings of its inaugural report, the 2018 ESO EMS Index. The Index tracks performance of EMS agencies nationwide across five metrics: Stroke assessment and documentation, overdose events, end-tidal carbon dioxide (ETCO2) monitoring, 12-lead electrocardiogram (EKG) use and aspirin administration for chest pain. Data used for the Index are from January 1, 2017 through December 31, 2017. “There are changes on the horizon for EMS agencies across the countr...
Source: JEMS: Journal of Emergency Medical Services News - February 15, 2018 Category: Emergency Medicine Authors: ESO Solutions Tags: Industry News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

An Aspirin a Day: Is the Benefit Worth the Risk?
Studies have shown that aspirin, the age old remedy for pain and fever, also thins the blood. Because of this property, it can also help to lower the chances of a heart attack or a stroke caused by a blood clot in the brain. And, although research has found that it only works in certain people (specifically, those with a history of heart attack or stroke) many Americans are inappropriately taking daily, low doses of aspirin as a preventative measure. In fact, researchers have found that about 12 percent of the of nearly 69,000 U.S. adults taking aspirin on a long-term basis should not have received the prescription in the ...
Source: Healthy Living - The Huffington Post - March 13, 2015 Category: Consumer Health News Source Type: news

U.S. Task Force Reconsiders Daily Low-Dose Aspirin Use for Preventing Heart Attacks in Adults Over 60
Older adults without heart disease shouldn’t take daily low-dose aspirin to prevent a first heart attack or stroke, an influential health guidelines group said in preliminary updated advice released Tuesday. Bleeding risks for adults in their 60s and up who haven’t had a heart attack or stroke outweigh any potential benefits from aspirin, the U.S. Preventive Services Task Force said in its draft guidance. For the first time, the panel said there may be a small benefit for adults in their 40s who have no bleeding risks. For those in their 50s, the panel softened advice and said evidence of benefit is less clear....
Source: TIME: Health - October 12, 2021 Category: Consumer Health News Authors: Lindsey Taylor/AP Tags: Uncategorized healthscienceclimate Research wire Source Type: news

A Serious Diagnosis Lacking Common Symptoms
​BY JENNIFER TUONG; IVAN KHARCHENKO; JEAN LUC AGARD; & AHMED RAZIUDDIN, MDA 65-year-old man who had HIV well-controlled with highly active antiretroviral therapy, hypertension, sciatica, and restless leg syndrome presented to the emergency department with left leg pain. He also had had chemotherapy and radiation for anal cancer. The patient said the pain had started 45 minutes earlier when he was sitting on the toilet.He described the pain as sore in quality and 10/10 on the pain scale. He reported that it had started in his lower back and radiated to his left leg. He said he had had no trauma or weakness to the regi...
Source: The Case Files - May 28, 2019 Category: Emergency Medicine Tags: Blog Posts Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Clinical Performance Measures that Matter —Are You Ready?
Conclusion The future will belong to those who can prove value. The use of a clinical performance dashboard and comparisons to national data will help to ensure that when the payers come knocking on our doors looking for "proof" that what we do enhances patient care and improves patient outcome, we’ll have an answer! This is the first in a yearlong series of articles developed by the Academy of International Mobile Healthcare Integration (AIMHI).The AIMHI article series is developed in partnership with JEMS to help educate EMS agencies on the hallmarks and attributes of high-performance/high-value EMS system de...
Source: JEMS Special Topics - December 11, 2018 Category: Emergency Medicine Authors: Wayne C. Harbour, NRP Tags: Exclusive Articles Operations Administration and Leadership Source Type: news

Aspirin Lowers Your Chances of a Heart Attack. But It ’s Not Safe for Everyone
As medications go, aspirin is often considered a wonder drug. Its pain-reliving, inflammation-taming powers can treat headaches, minor aches and pains and even lower the risk of heart disease, stroke and possibly even dementia. But all of those benefits may come at a price, according to the latest study to analyze aspirin’s risks and benefits, especially for people who take the drug as a way to prevent having a first heart event. In a study published in JAMA, researchers led by Dr. Sean Zheng at King’s College London found that the risks of aspirin — primarily of bleeding in the stomach and intestinal tra...
Source: TIME: Health - January 23, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease Source Type: news

Aspirin Lowers Your Chances of a Heart Attack. But It ’s Not Safe for Everyone, a New Study Says
As medications go, aspirin is often considered a wonder drug. Its pain-relieving, inflammation-taming powers can treat headaches, minor aches and pains and even lower the risk of heart disease, stroke and possibly even dementia. But all of those benefits may come at a price, according to the latest study to analyze aspirin’s risks and benefits, especially for people who take the drug as a way to prevent having a first heart event. In a study published in JAMA, researchers led by Dr. Sean Zheng at King’s College London found that the risks of aspirin — primarily of bleeding in the stomach and intestinal tr...
Source: TIME: Health - January 23, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease Source Type: news

European Resuscitation Council Guidelines 2021: First aid
The European Resuscitation Council has produced these first aid guidelines, which are based on the 2020 International Consensus on Cardiopulmonary Resuscitation Science with Treatment Recommendations. The topics include the first aid management of emergency medicine and trauma. For medical emergencies the following content is covered: recovery position, optimal positioning for shock, bronchodilator administration for asthma, recognition of stroke, early aspirin for chest pain, second dose of adrenaline for anaphylaxis, management of hypoglycaemia, oral rehydration solutions for treating exertion-related dehydration, manage...
Source: Resuscitation - March 24, 2021 Category: Emergency Medicine Authors: David A. Zideman, Eunice M. Singletary, Vere Borra, Pascal Cassan, Carmen D. Cimpoesu, Emmy De Buck, Therese Dj ärv, Anthony J. Handley, Barry Klaassen, Daniel Meyran, Emily Oliver, Kurtis Poole Source Type: research

E-248 Postpartum vertebral artery dissections: a report of 7 cases and literature review
ConclusionA limited cohort of 33 ppVADs exist in the literature. This study contributes 7 additional cases and suggests that, despite heterogenous management of ppVAD, the resulting outcomes were favorable.Disclosures V. Lazarov: None. A. Monteiro: None. F. Almayman: None. M. Waqas: None. J. Cappuzzo: None. E. Levy: None. A. Siddiqui: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lazarov, V., Monteiro, A., Almayman, F., Waqas, M., Cappuzzo, J., Levy, E., Siddiqui, A. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

Pediatric Moyamoya Revascularization Perioperative Care: A Modified Delphi Study
ConclusionsIn the absence of data supporting specific care practices before and after indirect revascularization surgery in children with moyamoya, this Delphi process defined areas of consensus among neurosurgeons, neurologists, and intensivists with moyamoya expertise. Research priorities identified include determining the role of continuous electroencephalography in postoperative moyamoya care, optimal perioperative blood pressure and hemoglobin targets, and the role of supplemental oxygen for treatment of suspected postoperative ischemia.
Source: Neurocritical Care - July 20, 2023 Category: Neurology Source Type: research

'Dying of heartache?' Heart problems linked to bereavement
Conclusion The study found that people were more likely to have AF for the first time in the weeks immediately after a bereavement, but that this raised risk does not last. Despite the headlines, this does not mean that anyone who's had a bereavement is at immediate risk of "dying of a broken heart". Atrial fibrillation is treatable and not usually life-threatening. Because this was an observational study, we cannot rule out the possibility that factors such as family history of atrial fibrillation or lifestyle factors could have affected the results, although the researcher's conclusion that this is a small poss...
Source: NHS News Feed - April 6, 2016 Category: Consumer Health News Tags: Heart/lungs Mental health Source Type: news